Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02177279
Other study ID # Wheat Bran 2001
Secondary ID
Status Completed
Phase N/A
First received June 19, 2014
Last updated July 7, 2014
Start date December 2011

Study information

Verified date July 2014
Source University of Aberdeen
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health Service
Study type Interventional

Clinical Trial Summary

There is a lot of evidence to suggest that eating a diet rich in cereals such as wheat bran are beneficial in protecting us from diseases such as heart disease, diabetes and cancer. It is still not clear exactly why this happens, but it is likely that the compounds which enter our bodies when we eat such products are responsible. In this study we plan to find out what these compounds are and where they are found. The investigators will do this by asking volunteers to eat a wheat-bran meal and then measuring the compounds that appear in blood, urine and stool samples over the next twenty-four hours. Once the investigators know how much and which compounds are present, we can then find out possible reasons why they are protective, for example by looking to see whether they are anti-inflammatory. We also plan to look at whether if having a diet which contains either a lot of wheat-bran products or very low amounts of these foods effects how they are absorbed by the body.

HYPOTHESIS: Wheat bran from ready-to-eat cereal has unique phytochemical profiles which are metabolized to compounds responsible for high cellular bioactivity imparting important health benefits.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date
Est. primary completion date February 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Volunteers will be healthy males or females and aged between 18 and 55 years who have a documented low (less than 1 portion per week) or high (more than or equal 5 portions per week) consumption of wheat bran and are able to give informed consent.

Exclusion Criteria:

- are taking any medicines prescribed by their general practitioner

- are taking drugs to lower high cholesterol levels or high blood pressure

- regularly take analgesics, antipyretic or anti-inflammatories

- regularly take nutritional supplements

- have taken antibiotics in the last three months

- have given a large blood donation in last three months

Study Design

Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label


Related Conditions & MeSH terms

  • Bio-availability of Wheat Bran Phytochemicals for the Systemic Circulation
  • Bio-availability of Wheat Bran Phytochemicals in the Human Gut

Intervention

Other:
Visit A high wheat bran

Visit B normal wheat bran

Follow up normal (8days) and high (1day) bran consumption


Locations

Country Name City State
United Kingdom Rowett Institute of Nutrition and Health, University of Aberdeen Aberdeen Aberdeenshire

Sponsors (2)

Lead Sponsor Collaborator
University of Aberdeen Kellogg's

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Human bioavailability of benzoic acids and derivatives from wheat bran cereals The analysis of the benzoic acid and derivatives metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24 h No
Primary Human bioavailability of cinnamic acids and derivatives from wheat bran cereals The analysis of the cinnamic acids and derivatives metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24h No
Primary Human bioavailability of phenylpropanoid dimers from wheat bran cereals The analysis of the phenylpropanoid dimers metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24h No
Primary Human bioavailability of phenyl propionic acids from wheat bran cereals The analysis of the phenyl propionic acids metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24h No
Primary Bioavailability of benzaldehydes from wheat bran The analysis of the benzaldehydes metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24h No
Primary Human bioavailability of acetophenones from wheat bran cereals The analysis of the acetophenones metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24h No
Primary Human bioavailability of lignans from wheat bran cereals The analysis of the lignans metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h). over 24 h No
Primary Short chain fatty acids profile after wheat bran consumption (acute) Short chain fatty acids profile in faecal samples at 0h (baseline) and 24h after wheat bran consumption (40g and 120g). 24 h No
Primary Short chain fatty acids profile after wheat bran consumption (chronic) Short chain fatty acids profile in in faecal samples at day 0 (baseline), day 5 (during 7 days consumption of 40g wheat bran cereals/day) and day 10 (after 120g wheat bran cereals consumption on day 9). 9 days No